The present invention relates to compounds of formula (I), tautomers, stereoisomers, and pharmaceutically acceptable salts thereof, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy (I) (wherein: Z represents an optionally substituted, 5- or 6-membered unsaturated heterocyclic group comprising at least one nitrogen atom L represents a 4-, 5- or 6-membered cycloalkyl group, preferably a cyclobutyl group each R1 independently represents F, CI, Br, I, C1-3 alkyl, C1-3 haloalkyl (e.g. -CF3), -CN, -OH or -NO2, preferably F, CI, Br or 1, e.g. CI or F each R2independently represents F, CI, Br, I, C1-3 alkyl, -CN, -OH or -NO2, preferably F, CI, Br, I or -CN, e.g. F or -CN X represents -NR3- or -0- R3 represents H or a C1-3 alkyl group (e.g. methyl) n is an integer from 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2, e.g 1 and m is an integer from 0 to 5, preferably 0 to 3, more preferably 0, 1 or 2, e.g. 0 or 1). These compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the WNT pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.La présente invention concerne des composés de formule (I), des tautomères, des stéréo-isomères et des sels pharmaceutiquement acceptables de ceux-ci, des procédés pour les préparer, des formulations pharmaceutiques contenant de tels composés et leur utilisation en thérapie (I) (dans laquelle : Z représente un groupe hétérocyclique insaturé à 5 ou 6 chaînons éventuellement substitué comprenant au moins un atome dazote L représente un groupe cycloalkyle à 4, 5 ou 6 chaînons, de préférence un groupe cyclobutyle chaque R1 représente indépendamment F, Cl, Br, I, un groupe alkyle en C1-3, haloalkyle en C1-3 (par exemple-CF3), -CN, -OH
